查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2011573

伴侣动物用药品市场：2026-2032年全球市场预测（依动物种类、产品类型、剂型、通路及治疗领域划分）

Companion Animal Health Market by Animal Type, Product Type, Formulation, Distribution Channel, Therapeutic Area - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，宠物药品市场价值将达到 471.3 亿美元，到 2026 年将成长至 550.1 亿美元，到 2032 年将达到 1,518.2 亿美元，复合年增长率为 18.18%。

主要市场统计数据
基准年 2025 471.3亿美元
预计年份：2026年 550.1亿美元
预测年份 2032 1518.2亿美元
复合年增长率 (%) 18.18%

对伴侣动物健康产业前景的展望，涵盖了不断增长的需求驱动因素、不断变化的相关人员以及策略重点。

受饲主期望变化、技术进步和护理模式演变的推动，伴侣动物医疗保健产业正经历快速转型。宠物饲主越来越将动物视为家庭成员，因此对先进诊断、专业营养管理和创新治疗方法的需求日益增长。同时，兽医诊所和销售合作伙伴也在调整其商业模式，并重组服务和产品交付方式，以适应远端医疗、居家监控和全通路购买行为。

数位转型、个人化照护模式和供应链韧性如何重塑兽医学领域的产品路径和竞争优势。

伴侣动物医疗保健生态系统正受到多重因素的共同影响而重塑，这些因素正在改变产品开发、临床实践和商业性合作模式。首先，数位化和连线健诊工具正从先导计画发展成为医疗服务的核心要素，从而能够早期发现慢性疾病，并促进兽医与饲主之间更频繁的远端互动。这些工具正在产生新的资料流，为以结果主导的价值提案和产品差异化提供支援。

本研究评估了累积关税压力将如何影响伴侣动物治疗、诊断和营养产品的整个供应链的采购、定价和准入。

主要贸易伙伴预期采取的关税措施可能会对进口原材料、成品或专用设备的伴侣动物保健公司产生累积影响。实际上，关税增加可能会提高製造商和经销商的接收成本，除非透过价格调整、采购管道变更或提高营运效率来抵消，否则可能会挤压利润空间。对于依赖跨境生产注射剂、诊断组件或药物活性成分的企业而言，关税风险可能会增加采购风险，并促使其将生产外包或实现供应商多元化。

详细的細項分析将动物种类、产品类型、配方选择和分销管道的趋势与临床应用和商业性机会联繫起来。

为了深入了解市场动态，必须从多个细分观点来掌握需求和采纳模式，从而指导产品设计和商业性执行。就动物种类而言，犬类仍然是预防医学和慢性病护理领域创新的主要目标，而猫则推动了隐藏式家庭护理和专业营养管理的普及。同时，马匹市场优先考虑具有独特临床路径的性能提升、繁殖和疼痛管理解决方案。就产品类型而言，诊断技术的进步，从影像学和体外诊断到连续监测，使得早期发现和更精准的治疗方法方案成为可能；而营养创新则侧重于针对生命週期需求和合併症管理的专用宠物食品配方和补充剂。药品涵盖范围广泛，从抗发炎药物和抗生素到内分泌疗法、镇痛药和驱虫药，每种药物都有其独特的监管规定、定价和合理使用注意事项。

影响美洲、欧洲、中东和非洲以及亚太市场差异化商业化策略的区域趋势。

临床实务、法规环境和消费者偏好的区域差异造就了鲜明的区域趋势，进而影响着参与企业和现有企业的策略重点。在美洲，成熟的兽医网络、较高的宠物拥有率以及消费者在预防保健和先进治疗方面的强烈消费意愿，使得市场准入和临床证据成为企业脱颖而出的关键手段。同时，供应链因素和报销机制也影响製造商在国家和地方市场中如何优先分配分销和促销投资。

策略重点和竞争对手策略，帮助企业在动物保健领域取得成功，结合临床可靠性、供应确定性和先进的分销管道。

在伴侣动物健康领域，竞争优势越来越取决于能否将科学可靠性与可扩展的商业性可行性结合。主要企业正优先建立整合诊断、治疗和营养解决方案的综合产品组合，并以疗效数据和临床医生培训计画为支持。策略联盟和选择性收购是拓展能力、获取专有技术以及加速进入相邻治疗和分销领域的常用方法。

为高阶主管提供可操作的策略措施，以增强证据产生、供应链韧性和跨通路的商业性差异化。

产业领导者应制定多管齐下的行动计划，旨在确保临床信心、优化供应链并加速商业性化应用。首先，应优先建立强有力的临床和真实世界证据，以证明产品在改善患者疗效和提升饲主满意度方面取得了可衡量的进步。这将有助于加强与兽医界意见领袖的关係，并巩固产品的高端定位。其次，应重新设计筹资策略，透过供应商多元化、尽可能本地化生产以及柔软性的库存管理来降低关税和物流风险，从而即使在供应中断的情况下也能维持服务水准。

结合从业者访谈、监管分析和情境规划的稳健混合方法研究途径，检验了商业性和临床发现。

本分析所依据的研究采用了一种混合方法，结合了定性和定量证据的收集、严谨的二手资料研究以及专家检验。关键资料来源包括对临床兽医、分销主管和产品开发经理的结构化访谈，从而深入观点临床工作流程、推广障碍和分销管道的经济效益。二手资料研究则纳入了监管指南、临床文献和行业趋势分析，以更好地理解访谈结果并识别系统性因素。

将临床创新、营运韧性和实证商业化联繫起来，作为动物医学长期成功的支柱，并得出相关结论。

总而言之，伴侣动物医疗保健正步入策略整合与创新时代，临床证据、供应链灵活性和完善的分销管道将决定最终的赢家。诊断技术和数位健康能力的进步正在改变医疗服务的节奏，使早期疗育成为可能，并为那些能够展现显着疗效的产品和服务创造了机会。兼顾配方便捷性和治疗效果的营养品和药品组合将越来越受到饲主的青睐，并获得临床医师的支持。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 伴侣动物用药品市场：依动物类型划分

  • 猫
  • 狗
  • 马

第九章 伴侣动物用药品市场：依产品类型划分

  • 诊断
    • 诊断影像
    • 体外诊断试剂
    • 监控设备
  • 营养
    • 宠物专用食品
    • 补充
  • 製药
    • 抗发炎药
    • 抗生素
    • 内分泌治疗
    • 疼痛管理
    • 杀虫剂
  • 疫苗

第十章 伴侣动物用药品剂型划分）

  • 注射药物
  • 口服
  • 外用

第十一章 伴侣动物用药品市场：依通路划分

  • 线上零售
  • 宠物专卖店
  • 药局
  • 动物医院

第十二章 伴侣动物用药品市场：依治疗领域划分

  • 循环系统
  • 牙科
  • 皮肤科
  • 内分泌
  • 整形外科
  • 寄生虫学

第十三章 伴侣动物用药品市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 伴侣动物用药品市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 伴侣动物用药品市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国伴侣动物用药品市场

第十七章：中国伴侣动物用药品市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Blue Buffalo Co., Ltd.
  • Boehringer Ingelheim Animal Health
  • Ceva Sante Animale
  • Covetrus
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Incorporated
  • Heska Corporation
  • Hill's Pet Nutrition, Inc.
  • IDEXX Laboratories, Inc.
  • Kindred Biosciences, Inc.
  • Mars Petcare Inc.
  • Merck Animal Health
  • Nestle Purina PetCare
  • Patterson Companies, Inc.
  • Royal Canin SAS
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-4330CC794B35

The Companion Animal Health Market was valued at USD 47.13 billion in 2025 and is projected to grow to USD 55.01 billion in 2026, with a CAGR of 18.18%, reaching USD 151.82 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 47.13 billion
Estimated Year [2026] USD 55.01 billion
Forecast Year [2032] USD 151.82 billion
CAGR (%) 18.18%

A compelling orientation to the companion animal health sector that frames rising demand drivers, stakeholder shifts, and priority areas for strategic action

The companion animal health landscape is undergoing an era of accelerated transformation driven by shifting owner expectations, technological advances, and evolving care models. Pet guardians increasingly view animals as integral family members, which has elevated demand for advanced diagnostics, specialized nutrition, and novel therapeutics. Concurrently, veterinary practices and channel partners are adapting operating models to accommodate telehealth, at-home monitoring, and omnichannel purchasing behaviors, reshaping how services and products are delivered.

Against this backdrop, commercial stakeholders must integrate clinical evidence, consumer insights, and supply chain resilience into strategic decision-making. Investment priorities are moving toward solutions that enable remote monitoring, improve diagnostic throughput, and deliver measurable clinical outcomes that resonate with both clinicians and owners. Moreover, regulatory scrutiny and antimicrobial stewardship initiatives are influencing formulary decisions and product development pathways. In combination, these dynamics create both challenges and opportunities for innovators, manufacturers, and distributors seeking to differentiate offerings and scale adoption across veterinary networks and retail channels.

Looking ahead, leaders who align scientific rigor with pragmatic commercialization strategies, and who anticipate shifting distribution and pricing pressures, will be best positioned to capture long-term value in this rapidly maturing sector.

How digital transformation, personalized care models, and supply chain resilience are reshaping product pathways and competitive advantage in animal health

The companion animal health ecosystem is being redefined by several convergent shifts that are transforming product development, clinical practice, and commercial engagement. First, digital and connected health tools are moving from pilot projects to core components of care delivery, enabling earlier detection of chronic conditions and more frequent remote interactions between veterinarians and owners. These tools are catalyzing new data streams that support outcome-driven value propositions and product differentiation.

Second, there is a pronounced move toward personalized and preventative approaches, with nutritional strategy and targeted therapeutics increasingly tailored to life stage, breed predispositions, and comorbidities. This trend is reinforced by growing consumer willingness to invest in premium care and by clinicians seeking evidence-based interventions that extend quality of life. Third, supply chain agility and sourcing transparency have become strategic imperatives as manufacturers and distributors respond to fluctuating input availability and evolving regulatory requirements. Together, these shifts elevate the importance of cross-functional collaboration among R&D, regulatory, and commercial teams.

Finally, the competitive landscape is intensifying as new entrants and incumbent manufacturers expand portfolios across diagnostics, nutrition, pharmaceuticals, and vaccines. The cumulative effect of these transformative shifts is a market where clinical credibility, digital integration, and channel sophistication determine who advances from niche adoption to mainstream acceptance.

Assessing how cumulative tariff pressures influence procurement, pricing, and access across companion animal therapeutics, diagnostics, and nutrition supply chains

Projected tariff actions originating from major trading partners can exert a cumulative influence on companion animal health companies that import raw materials, finished goods, or specialized equipment. In practical terms, higher duties increase landed costs for manufacturers and distributors, which can compress margins unless offset through pricing adjustments, re-sourcing, or operational efficiencies. For organizations that rely on cross-border production of injectables, diagnostics components, or pharmaceutical active ingredients, tariff exposure heightens procurement risk and may incentivize nearshoring or supplier diversification.

Beyond direct cost effects, tariff-induced shifts can create secondary impacts across supply chains and consumer behavior. For example, increased import costs may delay product launches or reduce promotional intensity as firms prioritize inventory allocation and working capital preservation. In turn, veterinarians and pet owners may experience constrained access to certain imported diagnostics or specialized nutritional formulations, prompting substitution toward locally produced alternatives or generics. Regulatory compliance and customs administration requirements can also extend lead times, making demand planning more complex and increasing the value of flexible inventory strategies.

To mitigate cumulative tariff impacts, stakeholders are advised to evaluate scenario-based sourcing strategies, renegotiate commercial terms where feasible, and accelerate product localization efforts. Ultimately, the resilience of manufacturing footprints and the agility of distribution networks will determine how effectively companies absorb tariff pressures while maintaining service levels for clinics and consumers.

Deep segmentation intelligence linking animal type, product architecture, formulation choices, and channel dynamics to clinical adoption and commercial opportunity

A granular view of market dynamics requires understanding demand and adoption patterns across multiple segmentation lenses that guide product design and commercial execution. When viewed through animal type, dogs remain a primary focus for preventive and chronic care innovations, while cats drive adoption in discreet, at-home treatments and specialized nutrition; equine markets prioritize performance, reproduction, and pain management solutions with distinct clinical pathways. Considering product type, diagnostic advances spanning imaging, in-vitro diagnostics, and continuous monitoring are enabling earlier detection and more precise treatment selection, whereas nutrition innovation emphasizes specialized pet food formulations and supplements that target lifecycle needs and comorbidity management. Pharmaceuticals encompass a range of modalities from anti-inflammatories and antibiotics to endocrine therapies, analgesics, and parasiticides, each with unique regulatory, pricing, and stewardship considerations.

Formulation choices-injectable, oral, and topical-continually influence prescribing behavior and owner adherence, with injectables favored for clinic-administered interventions, oral formulations supporting at-home chronic disease management, and topicals offering convenience for dermatological and parasitology indications. Distribution channel dynamics further shape access and purchasing patterns; online retail platforms are expanding reach and convenience, pet specialty stores maintain brand discovery roles, pharmacies offer trusted dispensing, and veterinary clinics remain central for professional guidance and point-of-care product use. Therapeutic area focus on cardiovascular, dental, dermatology, endocrine, orthopedic, and parasitology conditions highlights where clinical demand and innovation pipelines intersect, creating differentiated opportunities for targeted clinical evidence generation and tailored commercial strategies.

Taken together, these segmentation perspectives underscore the importance of integrated product planning that aligns formulation, channel strategy, and therapeutic positioning to clinical workflows and owner behaviors in order to accelerate adoption and sustain value.

Regional dynamics that dictate differentiated commercialization playbooks across the Americas, Europe Middle East & Africa, and Asia-Pacific markets

Geographic variation in clinical practice, regulatory environments, and consumer preferences creates distinct regional dynamics that shape strategic priorities for market entrants and incumbents alike. In the Americas, established veterinary networks, high pet ownership rates, and strong consumer propensity to spend on preventative and advanced care make market access and clinical evidence the primary levers for differentiation. Meanwhile, supply chain considerations and reimbursement structures influence how manufacturers prioritize distribution and promotional investments across national and subnational markets.

In Europe, Middle East & Africa, regulatory harmonization efforts coexist with diverse market maturity levels, creating opportunities for regionally tailored product registrations and differentiated channel strategies. Local clinical guidelines and antimicrobial stewardship programs in parts of this region can affect pharmaceutical utilization patterns, prompting manufacturers to emphasize stewardship-aligned messaging and diagnostic-enabled prescribing. Across the Asia-Pacific region, rapid pet ownership growth, expanding urban veterinary infrastructures, and rising disposable incomes are accelerating demand for premium nutrition, modern diagnostics, and accessible therapeutic options, while market entry strategies must account for varied regulatory landscapes and local manufacturing incentives.

Collectively, these regional insights point to the need for flexible commercialization frameworks that balance global clinical evidence generation with localized regulatory strategies, channel partnerships, and marketing approaches adapted to differing consumer behaviors and healthcare delivery models.

Strategic corporate priorities and competitive moves that combine clinical credibility, supply reliability, and channel sophistication to win in animal health

Competitive positioning in companion animal health is increasingly determined by the ability to combine scientific credibility with scalable commercial execution. Leading companies are prioritizing integrated portfolios that blend diagnostics, therapeutics, and nutritional solutions, supported by outcome data and clinician education programs. Strategic alliances and selective acquisitions are common approaches to broaden capability sets, access proprietary technologies, and accelerate entry into adjacent therapeutic or distribution segments.

Operational excellence in manufacturing and regulatory affairs remains critical, particularly for injectable biologics and advanced diagnostics that require stringent quality systems. Organizations that invest in supply chain visibility and digital forecasting tools gain advantages in inventory optimization and service continuity. On the commercial front, digital marketing, omnichannel sales enablement, and enhanced field force training support more effective engagement with veterinary practices and pet owners. Moreover, a growing emphasis on post-market evidence and real-world data collection strengthens clinical value propositions and supports payer or institutional procurement discussions.

In this competitive environment, nimble mid-sized firms can outmaneuver larger incumbents by focusing on niche therapeutic areas or by offering differentiated, clinician-facing diagnostic platforms. Conversely, large integrated players leverage scale to deliver global supply continuity and broad distribution, making partnerships with regional specialists an effective route to localized growth.

Actionable strategic moves for executives to strengthen evidence generation, supply resilience, and commercial differentiation across channels

Industry leaders should pursue a multi-pronged action agenda designed to secure clinical trust, optimize supply chains, and accelerate commercial adoption. First, prioritize the generation of robust clinical and real-world evidence that demonstrates measurable improvements in patient outcomes and owner satisfaction; this will strengthen relationships with veterinary opinion leaders and support premium positioning. Next, redesign sourcing strategies to reduce tariff and logistical exposure through supplier diversification, localized production where feasible, and inventory flexibility that preserves service levels during disruptions.

Simultaneously, invest in digital infrastructure that supports remote monitoring, telehealth integration, and omnichannel commerce, thereby capturing new engagement points and improving adherence. Commercial teams should develop channel-specific value propositions tailored to online retailers, specialty stores, pharmacies, and clinic partners, ensuring consistent messaging and streamlined fulfillment options. Additionally, embed antimicrobial stewardship and regulatory compliance into product strategies to mitigate reputational and regulatory risk while demonstrating clinical responsibility. Finally, explore partnerships and targeted M&A to acquire niche technologies or distribution reach, accelerating time to market for high-value innovations.

By implementing these recommendations, organizations can build resilient, evidence-driven portfolios that address clinical needs and changing owner expectations while safeguarding margin and access in an increasingly complex global environment.

Robust mixed-method research approach combining practitioner interviews, regulatory analysis, and scenario planning to validate commercial and clinical insights

The research underpinning this analysis draws on a blended methodology combining qualitative and quantitative evidence collection, rigorous secondary research, and expert validation. Primary inputs included structured interviews with practicing veterinarians, distribution executives, and product development leaders, providing perspective on clinical workflows, adoption barriers, and channel economics. Secondary research encompassed regulatory guidance, clinical literature, and industry trend analyses to contextualize interview findings and identify systemic drivers.

Analytical methods included cross-segmentation synthesis to evaluate how animal type, product typology, formulation, distribution channel, and therapeutic focus interact to influence adoption and commercial outcomes. Scenario planning and sensitivity analysis were applied to assess potential impacts of external shocks such as tariff adjustments and supply chain disruptions. All findings were triangulated with expert review panels to ensure interpretive rigor and practical relevance. Limitations of the study are acknowledged where data variability or rapidly evolving regulatory conditions may affect near-term applicability, and recommendations are provided with pathways for targeted validation through additional primary research or pilot programs.

This multi-method approach ensures the insights are grounded in clinical reality, commercially actionable, and adaptable to evolving market conditions.

Concluding synthesis that links clinical innovation, operational resilience, and evidence-driven commercialization as the pillars of long-term success in animal health

In summary, companion animal health is entering a period of strategic consolidation and innovation where clinical evidence, supply chain agility, and channel sophistication will determine winners. Diagnostic advancements and digital health capabilities are changing the tempo of care, enabling earlier intervention and creating opportunities for products and services that demonstrate clear outcome benefits. Nutrition and pharmaceutical portfolios that align formulation convenience with therapeutic effectiveness will capture increasing owner investment and clinician preference.

Tariff-related pressures and regional regulatory variation require proactive sourcing and market entry strategies to preserve access and margin. Companies that integrate robust evidence generation with adaptive manufacturing footprints and differentiated commercial models will be better positioned to navigate volatility and secure sustainable growth. Ultimately, the path to long-term success relies on translating clinical innovation into scalable, practitioner-validated solutions that meet evolving owner expectations while upholding standards of stewardship and safety.

Stakeholders who act now to align R&D priorities, operational capabilities, and market access strategies will create durable competitive advantage in a rapidly maturing market.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Companion Animal Health Market, by Animal Type

  • 8.1. Cat
  • 8.2. Dog
  • 8.3. Horse

9. Companion Animal Health Market, by Product Type

  • 9.1. Diagnostics
    • 9.1.1. Imaging
    • 9.1.2. In Vitro Diagnostics
    • 9.1.3. Monitoring Devices
  • 9.2. Nutrition
    • 9.2.1. Specialized Pet Food
    • 9.2.2. Supplements
  • 9.3. Pharmaceuticals
    • 9.3.1. Anti-Inflammatories
    • 9.3.2. Antibiotics
    • 9.3.3. Endocrine Treatments
    • 9.3.4. Pain Management
    • 9.3.5. Parasiticides
  • 9.4. Vaccines

10. Companion Animal Health Market, by Formulation

  • 10.1. Injectable
  • 10.2. Oral
  • 10.3. Topical

11. Companion Animal Health Market, by Distribution Channel

  • 11.1. Online Retail
  • 11.2. Pet Specialty Stores
  • 11.3. Pharmacies
  • 11.4. Veterinary Clinics

12. Companion Animal Health Market, by Therapeutic Area

  • 12.1. Cardiovascular
  • 12.2. Dental
  • 12.3. Dermatology
  • 12.4. Endocrine
  • 12.5. Orthopedic
  • 12.6. Parasitology

13. Companion Animal Health Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Companion Animal Health Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Companion Animal Health Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Companion Animal Health Market

17. China Companion Animal Health Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Blue Buffalo Co., Ltd.
  • 18.6. Boehringer Ingelheim Animal Health
  • 18.7. Ceva Sante Animale
  • 18.8. Covetrus
  • 18.9. Dechra Pharmaceuticals PLC
  • 18.10. Elanco Animal Health Incorporated
  • 18.11. Heska Corporation
  • 18.12. Hill's Pet Nutrition, Inc.
  • 18.13. IDEXX Laboratories, Inc.
  • 18.14. Kindred Biosciences, Inc.
  • 18.15. Mars Petcare Inc.
  • 18.16. Merck Animal Health
  • 18.17. Nestle Purina PetCare
  • 18.18. Patterson Companies, Inc.
  • 18.19. Royal Canin SAS
  • 18.20. Vetoquinol S.A.
  • 18.21. Virbac SA
  • 18.22. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COMPANION ANIMAL HEALTH MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COMPANION ANIMAL HEALTH MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES COMPANION ANIMAL HEALTH MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA COMPANION ANIMAL HEALTH MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY CAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY CAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY CAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DOG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DOG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DOG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY HORSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY HORSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY HORSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY IN VITRO DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY IN VITRO DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY IN VITRO DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY MONITORING DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY MONITORING DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY MONITORING DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY SPECIALIZED PET FOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY SPECIALIZED PET FOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY SPECIALIZED PET FOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ENDOCRINE TREATMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ENDOCRINE TREATMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ENDOCRINE TREATMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PARASITICIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PARASITICIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PARASITICIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PET SPECIALTY STORES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PET SPECIALTY STORES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PET SPECIALTY STORES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DENTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DENTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DENTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DERMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DERMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ENDOCRINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ENDOCRINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ENDOCRINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ORTHOPEDIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ORTHOPEDIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ORTHOPEDIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PARASITOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PARASITOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PARASITOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 183. GCC COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GCC COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. GCC COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. GCC COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 187. GCC COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 188. GCC COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 189. GCC COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 190. GCC COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. GCC COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 210. G7 COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. G7 COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. G7 COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. G7 COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 214. G7 COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 215. G7 COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 216. G7 COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 217. G7 COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. G7 COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 219. NATO COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. NATO COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. NATO COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. NATO COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 223. NATO COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 224. NATO COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 225. NATO COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 226. NATO COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. NATO COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES COMPANION ANIMAL HEALTH MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA COMPANION ANIMAL HEALTH MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)